Synlogic, Inc. - Common Stock (NQ:SYBX)

0.5600 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Synlogic, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria

March 28, 2023

From Synlogic, Inc.

Via GlobeNewswire

Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

March 20, 2023

Presentations included full data from both the Phase 2 Synpheny-1 Study in phenylketonuria and Phase 1 Study for SYNB1353 as a potential treatment for homocystinuria

From Synlogic, Inc.

Via GlobeNewswire

Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

March 10, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Synlogic Touts Positive Data From Rare Inherited Disorder Trial, Pivotal Study To Start Next Year ↗

October 18, 2022

Via Benzinga

Recap: Synlogic Q2 Earnings ↗

August 11, 2022

Synlogic (NASDAQ:SYBX) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 08, 2023

From Synlogic, Inc.

Via GlobeNewswire

Life Sciences Virtual Investor Forum Agenda Announced for March 9th

March 07, 2023

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

March 07, 2023

From Synlogic, Inc.

Via GlobeNewswire

Synlogic Announces Participation in Upcoming Investor and Industry Conferences

January 24, 2023

From Synlogic, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 20, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 20, 2023

Via Benzinga

Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

January 20, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 20, 2023

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 19, 2023

Via Benzinga

Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)

January 19, 2023

From Synlogic, Inc.

Via GlobeNewswire

Sidoti's January Micro-Cap Conference

January 17, 2023

Via ACCESSWIRE

Synlogic Provides Corporate Update and Outlook for 2023

January 05, 2023

From Synlogic, Inc.

Via GlobeNewswire

Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

January 03, 2023

From Synlogic, Inc.

Via GlobeNewswire

Synlogic's Experimental Drug Lowers Urinary Oxalate In Gastric Bypass Patients ↗

December 15, 2022

Synlogic Inc's (NASDAQ: SYBX) SYNB8802 has demonstrated proof of concept through a clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass...

Via Benzinga

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

December 15, 2022

From Synlogic, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 30, 2022

Via Benzinga

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

November 30, 2022

From Synlogic, Inc.

Via GlobeNewswire

BP To Rally Around 22%? Plus This Analyst Predicts $47 For YETI ↗

November 11, 2022

Piper Sandler boosted the price target on BP p.l.c. (NYSE: BP) from $37 to $40. BP shares rose 1.9% to close at $32.95 on Thursday.

Via Benzinga

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

November 10, 2022

From Synlogic, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

November 28, 2022

On Monday, 79 companies reached new 52-week lows.

Via Benzinga

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

October 18, 2022

From Synlogic, Inc.

Via GlobeNewswire

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 23, 2022

Via Benzinga

FDA Grants Fast Track Status To Synlogic's Rare Genetic Disorder Drug ↗

August 23, 2022

Synlogic, Inc. (NASDAQ: SYBX) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate SYNB1353 for the potential treatment of homocystinuria...

Via Benzinga

What Is Going on With Ginkgo Bioworks (DNA) Stock Today? ↗

August 12, 2022

DNA stock and other small biotech plays are rising on speculation about drugs like its candidate against gout.

Via InvestorPlace

Why Ginkgo Bioworks Stock Is Soaring Today ↗

August 11, 2022

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher Thursday after Synlogic Inc (NASDAQ: SYBX) announced a new drug candidate for the treatment of gout, which is being developed in...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.